Evidence map›Paper›PMID 25592281›Full record

ArticleMolecular medicine reports2015

Clinical significance of hepatocyte growth factor/c-Met expression in the assessment of gastric cancer progression.

Eiichiro Noguchi, Noboru Saito, Makio Kobayashi, Shingo Kameoka

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular medicine reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 35 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. A comparative study of RTK gene status between primary tumors, lymph-node metastases, and Krukenberg tumors.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2021
    Article
  8. Review
  9. Article
  10. Article
  11. Precision medicine in gastric cancer.World journal of gastrointestinal oncology · 2019
    Review
  12. Volumetric parameters onBMC cancer · 2019
    Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Eiichiro NoguchiDepartment of Surgery II, Tokyo Women's Medical University, Tokyo 162‑8666, Japan.
Noboru SaitoDepartment of Surgery II, Tokyo Women's Medical University, Tokyo 162‑8666, Japan.
Makio KobayashiDepartment of Pathology I, Tokyo Women's Medical University, Tokyo 162‑8666, Japan.
Shingo KameokaDepartment of Surgery II, Tokyo Women's Medical University, Tokyo 162‑8666, Japan.
Tokyo Women's Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Among the mechanisms that control cancer progression, cell mobility is a significant factor required for cellular liberation from the primary focus and infiltration. Hepatocyte growth factor (HGF) has been shown to facilitate cell mobility. In the present study, the clinical significance of the HGF/c‑Met pathway in the assessment of gastric cancer progression was evaluated. From a cohort of patients with gastric cancer who underwent surgical resection between April 1999 and March 2003, 110 subjects were randomly selected. Preoperative serum HGF levels were measured and various pathological factors were analyzed. Furthermore, 50 subjects were randomly selected from within this group and immunohistochemical staining of tissue preparations for HGF and its receptor c‑Met were performed. In the infiltrative growth pattern [(INF)α,β vs. INFγ], advanced progression was associated with elevated preoperative serum HGF levels (P<0.001). No correlation was identified between serum HGF levels and immunostaining for HGF or c‑Met in the tissue preparations. Immunostaining revealed a significant correlation between c‑Met expression and lymphatic vessel invasion (ly0.1 vs. 2.3; P=0.0416), lymph node metastasis (n0.1 vs. 2; P=0.0184) and maximum tumor diameter (≤50 mm vs. >50 mm; P=0.0469). Furthermore, c‑Met‑positivity was associated with a significant difference in overall survival (P=0.0342), despite stage I and II cases accounting for 82% of the total cohort (41 of 50 cases). These results suggested that the expression of the HGF/c‑Met pathway in gastric cancer may be a potential predictive factor for disease progression.

Indexed as

AdultAgedAged, 80 and overBiomarkers, TumorCase-Control StudiesDisease ProgressionFemaleGene ExpressionHepatocyte Growth FactorHumansImmunohistochemistryLymphatic MetastasisMaleMiddle AgedNeoplasm StagingPrognosisBiomarkers, TumorHepatocyte Growth FactorProto-Oncogene Proteins c-met

Identifiers

PMID25592281
PMCPMC4368069
OpenAlexW2136943768

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.